Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-8330. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 18/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 3/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8330 SCHEMBL388533 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL391764 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL18576802 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL391636 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL387711 | 0.90 | MAP2K1 (0.81) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL2341603 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL393158 | 0.89 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL12295137 | 0.89 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL570183 | 0.89 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL392221 | 0.89 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4676540-A1 | PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2026-01-14 | — | — | EP | disclosed |
| EP-4665720-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| CN-114058582-A | Methods and compositions for inducing hematopoietic cell differentiation | 菲特治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2022033492-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | MAP2K1 2217/4885MAP2K2 2209/4885MAP2K5 2313/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | MAP2K1 2428/4885MAP2K2 2807/4885MAP2K5 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.